BioMarin cuts deeper with 225 layoffs under CEO's new corporate strategy

The rightsizing at BioMarin continues to take its toll as CEO Alexander Hardy devises a new corporate strategy for the rare disease biotech.

BioMarin plans to cut about 225 employees, or about 7% of its global workforce, the California biotech said in a securities filing  Wednesday.